Logo image of RARX

Ra Pharmaceuticals Inc (RARX) Stock Fundamental Analysis

USA - NASDAQ:RARX -

47.995
-0.02 (-0.03%)
Last: 4/1/2020, 8:11:30 PM
47.995
0 (0%)
After Hours: 4/1/2020, 8:11:30 PM
No Fundamental Analysis report for RARX not available.

Ra Pharmaceuticals Inc

NASDAQ:RARX (4/1/2020, 8:11:30 PM)

After market: 47.995 0 (0%)

47.995

-0.02 (-0.03%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners90.82%
Inst Owner Change0%
Ins Owners39.41%
Ins Owner Change0%
Market Cap2.27B
Revenue(TTM)3.00M
Net Income(TTM)-102.69M
Analysts60
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 757.19
P/FCF N/A
P/OCF N/A
P/B 8.67
P/tB N/A
EV/EBITDA -19.09
EPS(TTM)-2.31
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.06
BVpS5.54
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -3565.97%
PM (TTM) -3422.93%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y1%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.79
Quick Ratio 14.79
Altman-Z 60.31
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.84%
EPS Next Y31.17%
EPS Next 2Y-32.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)20%
Revenue growth 3YN/A
Revenue growth 5Y-9.09%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Ra Pharmaceuticals Inc / RARX FAQ

What is the ChartMill fundamental rating of Ra Pharmaceuticals Inc (RARX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RARX.


Can you provide the valuation status for Ra Pharmaceuticals Inc?

ChartMill assigns a valuation rating of 1 / 10 to Ra Pharmaceuticals Inc (RARX). This can be considered as Overvalued.


Can you provide the profitability details for Ra Pharmaceuticals Inc?

Ra Pharmaceuticals Inc (RARX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for Ra Pharmaceuticals Inc?

The Earnings per Share (EPS) of Ra Pharmaceuticals Inc (RARX) is expected to grow by 31.17% in the next year.